BACKGROUND Elevated levels of inflammatory cytokines have been associated with poor
outcomes among COVID-19 patients. It is unknown, however, how these levels compare …

Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, it has rapidly
spread across many other countries. While the majority of patients were considered mild …

BACKGROUND. Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
coronavirus 2 (SARS-CoV-2), has become a pandemic. This study addresses the clinical …

Objective To delineate the characteristics and clinical significance of plasma inflammatory
cytokines altered in COVID-19. Design Retrospective, single-centre cohort study. Setting …

Background Markedly elevated levels of proinflammatory cytokines and defective type-I
interferon responses were reported in patients with coronavirus disease 2019 (COVID-19) …

Background: Biomarkers that would help prognosticate outcomes and guide treatment of
patients with severe coronavirus disease 2019 (COVID-19) are currently required. We aimed …

BACKGROUND. Identifying immune correlates of COVID-19 disease severity is an urgent
need for clinical management, vaccine evaluation, and drug development. Here, we present …

Summary Coronavirus disease 2019 (COVID‐19) is a clinical syndrome caused by the
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus. Patients can be …

Objectives The severity of Coronavirus Disease 2019 (COVID-19) is largely determined by
the immune response. First studies indicate altered lymphocyte counts and function …

Background Inflammatory biomarkers are associated with severity of coronavirus disease
2019 (COVID-19). However, direct comparisons of their utility in COVID-19 versus other …